{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:09:54Z","timestamp":1789582194094,"version":"build-2803163510"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Odevixibat is synthesized through chemical modification of Benzothiazepine's structure.\nIt is a tiny chemical that inhibits the ileal bile acid transporter and is used to treat a variety of\ncholestatic illnesses, including progressive familial intrahepatic cholestasis (PFIC). For cholestatic\npruritus and liver disease development, bile acid transporter inhibition is a unique treatment strategy.\nOdevixibat reduces enteric bile acid reuptake. Oral odevixibat was also studied in children\nwith cholestatic liver disease. Odevixibat received its first approval in the European Union (EU) in\nJuly 2021 for the treatment of PFIC in patients aged 6 months, followed by approval in the USA\nin August 2021 for the treatment of pruritus in PFIC patients aged 3 months. Bile acids in the distal\nileum can be reabsorbed by the ileal sodium\/bile acid cotransporter, a transport glycoprotein.\nOdevixibat is a sodium\/bile acid co-transporter reversible inhibitor. An average 3 mg once-daily\ndose of odevixibat for a week resulted in a 56% reduction in the area under the curve of bile acid.\nA daily dose of 1.5 mg resulted in a 43% decrease in the area under the curve for bile\nid. Odevixibat is also being evaluated in many countries for the treatment of other cholestatic illnesses,\nincluding Alagille syndrome and biliary atresia. This article reviews the updated information\non odevixibat with respect to its clinical pharmacology, mechanism of action, pharmacokinetics,\npharmacodynamics, metabolism, drug-drug interactions, pre-clinical studies, and clinical\ntrials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/2589977515666230308125238","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T06:19:36Z","timestamp":1678342776000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Odevixibat: A Review of a Bioactive Compound for the Treatment of\nPruritus Approved by the FDA"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-1089","authenticated-orcid":true,"given":"Mayur","family":"Porwal","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Kumar","sequence":"additional","affiliation":[{"name":"Drug Design Laboratory, School of Pharmaceutical Sciences, IFTM University, Moradabad, 244001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal Kishore","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, M.J.P.Rohilkhand University, Bareilly, 243001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Verma","sequence":"additional","affiliation":[{"name":"Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, 244001, Uttar Pradesh, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1152\/physrev.1941.21.2.357","volume":"21","author":"Rothman S.","year":"1941","unstructured":"Rothman S.; Physiology of itching. Physiol Rev 1941,21(2),357-381","journal-title":"Physiol Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0019-5154.198036","volume":"62","author":"Rajagopalan M.","year":"2017","unstructured":"Rajagopalan M.; Saraswat A.; Godse K.; Diagnosis and management of chronic pruritus: An expert consensus review. Indian J Dermatol 2017,62(1),7-17","journal-title":"Indian J Dermatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/archderm.139.11.1463","volume":"139","author":"St\u00e4nder S.","year":"2003","unstructured":"St\u00e4nder S.; Steinhoff M.; Schmelz M.; Weisshaar E.; Metze D.; Luger T.; Neurophysiology of pruritus. Arch Dermatol 2003,139(11),1463-1470","journal-title":"Arch Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1517\/14656566.2010.484420","volume":"11","author":"Patel T.","year":"2010","unstructured":"Patel T.; Yosipovitch G.; Therapy of pruritus. Expert Opin Pharmacother 2010,11(10),1673-1682","journal-title":"Expert Opin Pharmacother"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/j.1365-2133.2006.07430.x","volume":"155","author":"Weisshaar E.","year":"2006","unstructured":"Weisshaar E.; Apfelbacher C.; J\u00e4ger G.; Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006,155(5),957-964","journal-title":"Br J Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dth.12025","volume":"26","author":"Garibyan L.","year":"2013","unstructured":"Garibyan L.; Rheingold C.G.; Lerner E.A.; Understanding the pathophysiology of itch. Dermatol Ther 2013,26(2),84-91","journal-title":"Dermatol Ther"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.mcna.2021.04.007","volume":"105","author":"Lipman Z.M.","year":"2021","unstructured":"Lipman Z.M.; Ingrasci G.; Yosipovitch G.; Approach to the patient with chronic pruritus. Med Clin North Am 2021,105(4),699-721","journal-title":"Med Clin North Am"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/bjd.12267","volume":"168","author":"St\u00e4nder S.","year":"2013","unstructured":"St\u00e4nder S.; Stumpf A.; Osada N.; Wilp S.; Chatzigeorgakidis E.; Pfleiderer B.; Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol 2013,168(6),1273-1280","journal-title":"Br J Dermatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1523\/JNEUROSCI.17-20-08003.1997","volume":"17","author":"Schmelz M.","year":"1997","unstructured":"Schmelz M.; Schmidt R.; Bickel A.; Handwerker H.O.; Torebj\u00f6rk H.E.; Specific C-receptors for itch in human skin. J Neurosci 1997,17(20),8003-8008","journal-title":"J Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrn1950","volume":"7","author":"Ikoma A.","year":"2006","unstructured":"Ikoma A.; Steinhoff M.; St\u00e4nder S.; Yosipovitch G.; Schmelz M.; The neurobiology of itch. Nat Rev Neurosci 2006,7(7),535-547","journal-title":"Nat Rev Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","volume":"147","author":"Kini S.P.","year":"2011","unstructured":"Kini S.P.; DeLong L.K.; Veledar E.; McKenzie-Brown A.M.; Schaufele M.; Chen S.C.; The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol 2011,147(10),1153-1156","journal-title":"Arch Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1600-0536.1992.tb05253.x","volume":"27","author":"Jovanovic M.","year":"1992","unstructured":"Jovanovic M.; Oliwifcki S.; Beck M.H.; Occupational contact urticaria from beef associated with hand eczema. Contact Dermat 1992,27(3),188-189","journal-title":"Contact Dermat"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.0105-1873.2004.00413.x","volume":"51","author":"Jovanovi\u0107 M.","year":"2004","unstructured":"Jovanovi\u0107 M.; Polja\u010dki M.; Mimica-Duki\u0107 N.; Sesquiterpene lactone mix patch testing supplemented with dandelion extract in patients with allergic contact dermatitis, atopic dermatitis and non-allergic chronic inflammatory skin diseases. Contact Dermat 2004,51(3),101-110","journal-title":"Contact Dermat"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nrneurol.2014.99","volume":"10","author":"Misery L.","year":"2014","unstructured":"Misery L.; Brenaut E.; Le Garrec R.; Neuropathic pruritus. Nat Rev Neurol 2014,10(7),408-416","journal-title":"Nat Rev Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tins.2010.09.002","volume":"33","author":"Davidson S.","year":"2010","unstructured":"Davidson S.; Giesler G.J.; The multiple pathways for itch and their interactions with pain. Trends Neurosci 2010,33(12),550-558","journal-title":"Trends Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11882-010-0117-z","volume":"10","author":"Greaves M.W.","year":"2010","unstructured":"Greaves M.W.; Pathogenesis and treatment of pruritus. Curr Allergy Asthma Rep 2010,10(4),236-242","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41398-018-0097-7","volume":"8","author":"Misery L.","year":"2018","unstructured":"Misery L.; Dutray S.; Chastaing M.; Schollhammer M.; Consoli S.G.; Consoli S.M.; Psychogenic itch. Transl Psychiatry 2018,8(1),52","journal-title":"Transl Psychiatry"},{"key":"ref=18","first-page":"195","volume":"84","author":"Reamy B.V.","year":"2011","unstructured":"Reamy B.V.; Bunt C.W.; Fletcher S.; A diagnostic approach to pruritus. Am Fam Physician 2011,84(2),195-202","journal-title":"Am Fam Physician"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/jama.1956.02970070036009","volume":"161","author":"Robinson H.M.","year":"1956","unstructured":"Robinson H.M.; Robinson R.C.; Strahan J.F.; Hydroxyzine (atarax) hydrochloride in dermatological therapy. J Am Med Assoc 1956,161(7),604-606","journal-title":"J Am Med Assoc"},{"key":"ref=20","first-page":"105","volume":"3","author":"Kar S.","year":"2012","unstructured":"Kar S.; Krishnan A.; Preetha K.; Mohankar A.; A review of antihistamines used during pregnancy. J Pharmacol Pharmacother 2012,3(2),105-108","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/hup.713","volume":"20","author":"Tashiro M.","year":"2005","unstructured":"Tashiro M.; Horikawa E.; Mochizuki H.; Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol 2005,20(7),501-509","journal-title":"Hum Psychopharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2500\/aap.2007.28.3015","volume":"28","author":"Banerji A.","year":"2007","unstructured":"Banerji A.; Long A.A.; Camargo C.A.; Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: A literature review. Allergy Asthma Proc 2007,28(4),418-426","journal-title":"Allergy Asthma Proc"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.smrv.2014.06.001","volume":"19","author":"Yeung W.F.","year":"2015","unstructured":"Yeung W.F.; Chung K.F.; Yung K.P.; Ng T.H.Y.; Doxepin for insomnia: A systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015,19,75-83","journal-title":"Sleep Med Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11200810-000000000-00000","volume":"24","author":"Weber J.","year":"2010","unstructured":"Weber J.; Siddiqui M.A.A.; Wagstaff A.J.; McCormack P.L.; Low-Dose Doxepin. CNS Drugs 2010,24(8),713-720","journal-title":"CNS Drugs"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.4088\/JCP.v69n1005","volume":"69","author":"Scharf M.","year":"2008","unstructured":"Scharf M.; Rogowski R.; Hull S.; Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008,69(10),1557-1564","journal-title":"J Clin Psychiatry"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0140-6736(94)90820-6","volume":"343","author":"Chadwick D. Gabapentin","year":"1994","unstructured":"Chadwick D. Gabapentin;  Lancet 1994,343(8889),89-91","journal-title":"Lancet"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"Bockbrader H.N.","year":"2010","unstructured":"Bockbrader H.N.; Wesche D.; Miller R.; Chapel S.; Janiczek N.; Burger P.; A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010,49(10),661-669","journal-title":"Clin Pharmacokinet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"CD007938","DOI":"10.1002\/14651858.CD007938.pub4","volume":"6","author":"Wiffen P.J.","year":"2017","unstructured":"Wiffen P.J.; Derry S.; Bell R.F.; Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017,6(6),CD007938","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00007691-200306000-00009","volume":"25","author":"Yuan C.M.","year":"2003","unstructured":"Yuan C.M.; Spandorfer P.R.; Miller S.L.; Henretig F.M.; Shaw L.M.; Evaluation of tricyclic antidepressant false positivity in a pediatric case of cyproheptadine (periactin) overdose. Ther Drug Monit 2003,25(3),299-304","journal-title":"Ther Drug Monit"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/apa.13477","volume":"105","author":"Merhar S.L.","year":"2016","unstructured":"Merhar S.L.; Pentiuk S.P.; Mukkada V.A.; Meinzen-Derr J.; Kaul A.; Butler D.R.; A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects. Acta Paediatr 2016,105(8),967-970","journal-title":"Acta Paediatr"},{"key":"ref=31","first-page":"15","volume":"25","author":"Scott D.W.","year":"2000","unstructured":"Scott D.W.; Rothstein E.; Miller W.H.; A clinical study on the efficacy of two commercial veterinary pramoxine cream rinses in the management of pruritus in atopic dogs. Canine Pract 2000,25(2),15-17","journal-title":"Canine Pract"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/09546630802441218","volume":"20","author":"Young T.A.","year":"2009","unstructured":"Young T.A.; Patel T.S.; Camacho F.; A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009,20(2),76-81","journal-title":"J Dermatolog Treat"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3458.2001.tb00195.x","volume":"7","author":"Ye J.H.","year":"2001","unstructured":"Ye J.H.; Ponnudurai R.; Schaefer R.; Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001,7(2),199-213","journal-title":"CNS Drug Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0272-6386(00)70251-4","volume":"35","author":"Ashmore S.D.","year":"2000","unstructured":"Ashmore S.D.; Jones C.H.; Newstead C.G.; Daly M.J.; Chrystyn H.; Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000,35(5),827-831","journal-title":"Am J Kidney Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/230949901302100222","volume":"21","author":"Mak M.F.","year":"2013","unstructured":"Mak M.F.; Li W.; Mahadev A.; Calamine lotion to reduce skin irritation in children with cast immobilisation. J Orthop Surg (Hong Kong) 2013,21(2),221-225","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"ref=36","first-page":"42","volume":"12","author":"Liang S.E.","year":"2019","unstructured":"Liang S.E.; Homayounfar G.; Heilman E.; Liebman T.N.; Acquired ichthyosis in the setting of active pulmonary tuberculosis. J Clin Aesthet Dermatol 2019,12(6),42-44","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=37","first-page":"9","volume":"43","author":"Wildsmith J.A.","year":"2011","unstructured":"Wildsmith J.A.; Lidocaine: A more complex story than\u2019simple\u2019chemistry suggests. Proc History Anaesthesia Society 2011,43,9-16","journal-title":"Proc History Anaesthesia Society"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejphar.2009.06.026","volume":"616","author":"Inan S.","year":"2009","unstructured":"Inan S.; Dun N.J.; Cowan A.; Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5\u2032-guanidinonaltrindole-induced scratching models in mice: Behavioral and neuroanatomical evidence. Eur J Pharmacol 2009,616(1-3),141-146","journal-title":"Eur J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40248-019-0203-6","volume":"14","author":"Corsico A.G.","year":"2019","unstructured":"Corsico A.G.; Leonardi S.; Licari A.; Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidiscip Respir Med 2019,14(1),40","journal-title":"Multidiscip Respir Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000351843","volume":"92","author":"Zhang L.","year":"2013","unstructured":"Zhang L.; Cheng L.; Hong J.; The clinical use of cetirizine in the treatment of allergic rhinitis. Pharmacology 2013,92(1-2),14-25","journal-title":"Pharmacology"},{"key":"ref=41","author":"Aronson J.K.","year":"2015","unstructured":"Aronson J.K.;  Meyler\u2019s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions 2015","journal-title":"Meyler\u2019s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bmj.331.7511.292-a","volume":"331","author":"Sweetman S.C.","year":"2005","unstructured":"Sweetman S.C.; Dose adjustment in renal impairment: Response from Martindale: The Complete Drug Reference. BMJ 2005,331(7511),292-293","journal-title":"BMJ"},{"key":"ref=43","first-page":"369","volume":"62","author":"Nounou M.M.","year":"2005","unstructured":"Nounou M.M.; El-Khordagui L.K.; Khalafallah N.; Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm 2005,62(5),369-379","journal-title":"Acta Pol Pharm"},{"key":"ref=44","author":"Day C.","year":"2011","unstructured":"Day C.; Bailey C.J.; Metformin. xPharm: the comprehensive pharmacology reference Amsterdam Elsevier 2011","journal-title":"xPharm: the comprehensive pharmacology reference Amsterdam Elsevier"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00003088-199426030-00004","volume":"26","author":"Altamura A.C.","year":"1994","unstructured":"Altamura A.C.; Moro A.R.; Percudani M.; Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994,26(3),201-214","journal-title":"Clin Pharmacokinet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00003495-198632060-00002","volume":"32","author":"Benfield P.","year":"1986","unstructured":"Benfield P.; Heel R.C.; Lewis S.P.; Fluoxetine. Drugs 1986,32(6),481-508","journal-title":"Drugs"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CE.S133661","volume":"13","author":"Eshtiaghi P.","year":"2018","unstructured":"Eshtiaghi P.; Gooderham M.J.; Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid 2018,13,13-20","journal-title":"Core Evid"},{"key":"ref=48","first-page":"532","volume":"43","author":"D\u2019Ippolito D.","year":"2018","unstructured":"D\u2019Ippolito D.; Pisano M.; Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. PandT 2018,43(9),532-535","journal-title":"PandT"},{"key":"ref=49","author":"James D.K.","year":"2010","unstructured":"James D.K.; Steer P.J.; Weiner C.P.; Gonik B.;  High Risk Pregnancy E-Book: Management Options-Expert Consult 2010","journal-title":"High Risk Pregnancy E-Book: Management Options-Expert Consult"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/1573407214666180717111419","volume":"15","author":"Mishra A.K.","year":"2020","unstructured":"Mishra A.K.; Kumar A.; Singh H.; Verma S.; Sahu J.K.; Mishra A.; Chemistry and pharmacology of luliconazole (imidazole derivative): a novel bioactive compound to treat fungal infection-a mini review. Curr Bioact Compd 2020,15(6),602-609","journal-title":"Curr Bioact Compd"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/CE.S49629","volume":"9","author":"Khanna D.","year":"2014","unstructured":"Khanna D.; Bharti S.; Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid 2014,9,113-124","journal-title":"Core Evid"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/myc.12168","volume":"57","author":"Scher R.K.","year":"2014","unstructured":"Scher R.K.; Nakamura N.; Tavakkol A.; Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses 2014,57(7),389-393","journal-title":"Mycoses"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/3527608001.ch22","author":"Tuba Z.","year":"2006","unstructured":"Tuba Z.; Mah\u00f3 S.; S\u00e1nta C.;  Corticosteroids: From natural products to useful analogues Analogue-based Drug Discovery 2006,419","journal-title":"Corticosteroids: From natural products to useful analogues Analogue-based Drug Discovery"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000081680","volume":"18","author":"Roeder A.","year":"2005","unstructured":"Roeder A.; Schaller M.; Sch\u00e4fer-Korting M.; Korting H.C.; Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases. Skin Pharmacol Physiol 2005,18(1),3-11","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/0091-6749(93)90317-9","volume":"91","author":"Vanas A.","year":"1993","unstructured":"Vanas A.; Bronsky E.; Dockhorn R.; Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol 1993,91(6),1146-1154","journal-title":"J Allergy Clin Immunol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000210746","volume":"1","author":"Wahlgren C.F.","year":"1988","unstructured":"Wahlgren C.F.; H\u00e4germark \u00d6.; Bergstr\u00f6m R.; Hedin B.; Evaluation of a new method of assessing pruritus and antipruritic drugs. Skin Pharmacol Physiol 1988,1(1),3-13","journal-title":"Skin Pharmacol Physiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"105913","DOI":"10.1016\/j.ejps.2021.105913","volume":"165","author":"Bonner J.J.","year":"2021","unstructured":"Bonner J.J.; Burt H.; Johnson T.N.; Whitaker M.J.; Porter J.; Ross R.J.; Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. Eur J Pharm Sci 2021,165,105913","journal-title":"Eur J Pharm Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1468-3083.2002.00380.x","volume":"16","author":"Gupta A.K.","year":"2002","unstructured":"Gupta A.K.; Adamiak A.; Chow M.; Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002,16(2),100-114","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejps.2017.12.017","volume":"114","author":"Dheer D.","year":"2018","unstructured":"Dheer D.; Jyoti, Gupta PN, Shankar R. Tacrolimus: An updated review on delivering strategies for multifarious diseases. Eur J Pharm Sci 2018,114,217-227","journal-title":"Eur J Pharm Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2165\/00003495-199346040-00009","volume":"46","author":"Peters D.H.","year":"1993","unstructured":"Peters D.H.; Fitton A.; Plosker G.L.; Faulds D.; Tacrolimus. Drugs 1993,46(4),746-794","journal-title":"Drugs"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0190-9622(86)70164-3","volume":"15","author":"Olsen E.A.","year":"1986","unstructured":"Olsen E.A.; Cornell R.C.; Topical clobetasol-17-propionate: Review of its clinical efficacy and safety. J Am Acad Dermatol 1986,15(2),246-255","journal-title":"J Am Acad Dermatol"},{"key":"ref=62","first-page":"22","volume":"13","author":"Del Rosso J.Q.","year":"2020","unstructured":"Del Rosso J.Q.; Topical corticosteroid therapy for psoriasis\u2014a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol 2020,13(2),22-29","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00063030-199809010-00006","volume":"9","author":"Spencer C.M.","year":"1998","unstructured":"Spencer C.M.; Wagstaff A.J.; Prednicarbate. BioDrugs 1998,9(1),61-86","journal-title":"BioDrugs"},{"key":"ref=64","first-page":"553","volume":"3","author":"Gupta A.K.","year":"2004","unstructured":"Gupta A.K.; Chow M.; Prednicarbate (dermatop): a review. J Drugs Dermatol 2004,3(5),553-556","journal-title":"J Drugs Dermatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"104675","DOI":"10.1016\/j.fitote.2020.104675","volume":"146","author":"Wang J.","year":"2020","unstructured":"Wang J.; Su B.; Jiang H.; Traditional uses, phytochemistry and pharmacological activities of the genus Cinnamomum (Lauraceae): A review. Fitoterapia 2020,146,104675","journal-title":"Fitoterapia"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.5348\/ijcri-2013-02-267-RA-1","volume":"4","author":"Hamidpour R.","year":"2013","unstructured":"Hamidpour R.; Hamidpour S.; Hamidpour M.; Shahlari M.; Camphor (Cinnamomum camphora), a traditional remedy with the history of treating several diseases. Int J Case Rep Imag 2013,4(2),86-89","journal-title":"Int J Case Rep Imag"},{"key":"ref=67","unstructured":"Biospace. Albireo Announces FDA Approval of Bylvay\u2122 (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC). Available from:  (Accessed on: Dec 2021)."},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2018.12.018","volume":"161","author":"Donkers J.M.","year":"2019","unstructured":"Donkers J.M.; Roscam Abbing R.L.P.; van de Graaf S.F.J.; Developments in bile salt based therapies: A critical overview. Biochem Pharmacol 2019,161,1-13","journal-title":"Biochem Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"110835","DOI":"10.1016\/j.biopha.2020.110835","volume":"132","author":"Yang N.","year":"2020","unstructured":"Yang N.; Dong Y.Q.; Jia G.X.; ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery. Biomed Pharmacother 2020,132,110835","journal-title":"Biomed Pharmacother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","volume":"64","author":"Baghdasaryan A.","year":"2016","unstructured":"Baghdasaryan A.; Fuchs C.D.; \u00d6sterreicher C.H.; Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol 2016,64(3),674-681","journal-title":"J Hepatol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jhep.2014.02.006","volume":"60","author":"Fickert P.","year":"2014","unstructured":"Fickert P.; Pollheimer M.J.; Beuers U.; Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014,60(6),1290-1303","journal-title":"J Hepatol"},{"key":"ref=72","unstructured":"Bylvay: EPAR-Product information. Available from:  (Accessed on Sep, 2021)."},{"key":"ref=73","unstructured":"BYLVAY (Odevixibat Capsules) drug. Available from:  (Accessed on Dec, 2021)."},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/liv.14553","volume":"40","author":"Kamath B.M.","year":"2020","unstructured":"Kamath B.M.; Stein P.; Houwen R.H.J.; Verkade H.J.; Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int 2020,40(8),1812-1822","journal-title":"Liver Int"},{"key":"ref=75","unstructured":"Bifeprunox - Atypical Antipsychotic Drug. 2004. Available from:  (Accessed on: Dec, 2021)."},{"key":"ref=76","unstructured":"Reimbursed Access to Bylvay\u00ae (odevixibat) Approved in France for Patients with PFIC 1 and 2. Available from:"},{"key":"ref=77","unstructured":"Albireo announces FDA approval of Bylvay\u2122 (odevixibat), the first drug treatment for patients with progressive familial intrahepatic cholestasis (PFIC). Available from:  (Accessed on: July 2022)."},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"Chiang J.Y.","year":"2013","unstructured":"Chiang J.Y.; Bile acid metabolism and signaling. Compr Physiol 2013,3(3),1191-1212","journal-title":"Compr Physiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"Russell D.W.","year":"2003","unstructured":"Russell D.W.; The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003,72(1),137-174","journal-title":"Annu Rev Biochem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","volume":"14","author":"Karpen S.J.","year":"2020","unstructured":"Karpen S.J.; Kelly D.; Mack C.; Stein P.; Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int 2020,14(5),677-689","journal-title":"Hepatol Int"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11901-020-00517-x","volume":"19","author":"D\u00fcll M.M.","year":"2020","unstructured":"D\u00fcll M.M.; Kremer A.E.; Newer approaches to the management of pruritus in cholestatic liver disease. Curr Hepatol Rep 2020,19(2),86-95","journal-title":"Curr Hepatol Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1152\/physrev.00054.2017","volume":"98","author":"Hegyi P.","year":"2018","unstructured":"Hegyi P.; Mal\u00e9th J.; Walters J.R.; Hofmann A.F.; Keely S.J.; Guts and gall: bile acids in regulation of intestinal epithelial function in health and disease. Physiol Rev 2018,98(4),1983-2023","journal-title":"Physiol Rev"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e234185","DOI":"10.1136\/bcr-2019-234185","volume":"13","author":"Slavetinsky C.","year":"2020","unstructured":"Slavetinsky C.; Sturm E.; Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis. BMJ Case Reports CP 2020,13(6),e234185","journal-title":"BMJ Case Reports CP"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","volume":"8","author":"Al-Dury S.","year":"2018","unstructured":"Al-Dury S.; Wahlstr\u00f6m A.; Wahlin S.; Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep 2018,8(1),6658","journal-title":"Sci Rep"},{"key":"ref=85","first-page":"781","volume":"72","author":"Grammatikopoulos T.","year":"2021","unstructured":"Grammatikopoulos T.; Thompson C.; Soufi N.; Long-term safety and tolerability of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: results from the phase 3 PEDFIC 1 and PEDFIC 2 studies. J Pediatr Gastroenterol Nutr 2021,72(Suppl. 1),781-782","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref=86","unstructured":"Odevixibat. Available from:  (Accessed on Dec, 2021)."},{"key":"ref=87","unstructured":"MedChemExpresss. Available from:  (Accessed on Dec, 2021)."},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jval.2021.04.774","volume":"24","author":"Thompson R.J.","year":"2021","unstructured":"Thompson R.J.; Kjems L.; Hardikar W.; Lainka E.; Calvo P.L.; Horn P.; PMU62 Improved quality of life in children with progressive familial intrahepatic cholestasis following 24 weeks of treatment with odevixibat, an ileal bile acid transporter inhibitor: Results from the phase 3 PEDFIC 1 study. Value Health 2021,24,S155","journal-title":"Value Health"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"Thompson R.J.","year":"2022","unstructured":"Thompson R.J.; Arnell H.; Artan R.; Odevixibat treatment in progressive familial intrahepatic cholestasis: A randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2022,7(9),830-842","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41575-022-00667-x","volume":"19","author":"Ray K.","year":"2022","unstructured":"Ray K.; Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis. Nat Rev Gastroenterol Hepatol 2022,19(9),556","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","volume":"45","author":"Baumann U.","year":"2021","unstructured":"Baumann U.; Sturm E.; Lacaille F.; Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. Clin Res Hepatol Gastroenterol 2021,45(5),101751","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1055\/s-0041-1730951","volume":"41","author":"Kohut T.J.","year":"2021","unstructured":"Kohut T.J.; Gilbert M.A.; Loomes K.M.; Alagille syndrome: A focused review on clinical features, genetics, and treatment. Semin Liver Dis 2021,41(4),525-537","journal-title":"Semin Liver Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1007\/s12325-022-02262-7","volume":"39","author":"Gwaltney C.","year":"2022","unstructured":"Gwaltney C.; Ivanescu C.; Karlsson L.; Warholic N.; Kjems L.; Horn P.; Validation of the PRUCISION instruments in pediatric patients with progressive familial intrahepatic cholestasis. Adv Ther 2022,39(11),5105-5125","journal-title":"Adv Ther"},{"key":"ref=94","unstructured":"Native Liver Survival in Odevixibat sBA Responders: Data From the Pedfic Studies in Patients With Progressive Familial Intrahepatic Cholestasis. Available from:  (Accessed on March, 2022)."}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230308125238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/214475\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977515666230308125238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T08:54:20Z","timestamp":1698828860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/214475\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977515666230308125238","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}